low - Pharmaceutical and biotech R&D spending is highly inelastic and driven by patent cliffs, FDA approval pipelines, and long-term clinical trial commitments rather than GDP fluctuations. Veeva's mission-critical systems for regulatory compliance and commercial operations are last-budget-to-cut. However, biotech funding conditions (IPO markets, venture capital availability) can affect new customer formation in the 500-employee-and-below segment.

Moderate indirect sensitivity through biotech customer funding. Rising rates compress biotech valuations and reduce venture/IPO funding, which can slow new customer acquisition among smaller biotech firms (estimated 30-40% of customer base). However, large pharma customers (60-70% of revenue) are rate-insensitive. Veeva's own balance sheet has minimal debt and $2B+ cash, so direct financing impact is negligible. Higher rates may compress valuation multiples from historical 12-15x forward revenue to 8-10x range.

growth - Veeva attracts quality growth investors seeking durable 15-20% revenue growth with expanding margins in a defensive end-market. The 74% gross margin, asset-light model, and recurring revenue appeal to SaaS-focused growth managers. Recent 36% drawdown reflects multiple compression from 15x forward revenue to 9-10x as interest rates rose, creating potential value entry point for growth-at-reasonable-price (GARP) investors. Not a dividend stock (no dividend paid) and limited appeal to deep value given still-premium valuation.